This article provides drugs containing liver-targeting specific ligands and thyroxine receptor agonists in the structure. The liver-targeting specific ligands and thyroxine receptor agonists are connected through branch chains, linkers and connecting chains to form A new drug structure. Thyroid hormone receptors (TRs) are divided into two subtypes, TR-α and TR-β. Among them, TR-β is mainly expressed in the liver, and TR-α is mainly expressed in the heart and nervous system. In some embodiments, the drugs provided herein are expected to have a liver-targeting effect, which can specifically bring thyroxine receptor agonists into the liver, so that it does not enter the heart and other tissues, and can prevent thyroxine from being affected. The effect of body agonists on other tissues causes side effects and maintains its efficacy in treating lipid metabolism disorders and related complications.本文提供了結構中含有肝靶向特異性配體和甲狀腺素受體激動劑的藥物，是通過支鏈、接頭和連接鏈將肝靶向特異性配體和甲狀腺素受體激動劑連接，成為一個新的藥物結構。甲狀腺激素受體（TRs）分為兩個亞型，TR-α和TR-β，其中TR-β主要表達在肝臟，TR-α主要表達在心臟、神經系統等。在某些實施方案中，預期本文提供的藥物具有肝靶向的作用，可以把甲狀腺素受體激動劑特異性的帶入到肝臟，使其不進入到心臟和其他組織，可以避免甲狀腺素受體激動劑對其他組織的作用引發副作用，並保持其治療脂質代謝紊亂及相關併發症的療效。
